A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).Jochen H. Lorch, David A. Barbie, Jonathan D. Schoenfeld et al.|Journal of Clinical Oncology|2020Cited by 65